Emergent Initiates Quality Enhancement Plan For Troubled Baltimore Vaccine Facility

  • Emergent BioSolutions Inc EBS has been in headlines after its Baltimore plant has drawn the scrutiny of the FDA.
  • manufacturing mix-up ruined 15 million Johnson & Johnson JNJ COVID-19 vaccine doses at the Baltimore plant.
  • Last month, the FDA completed its inspection of the troubled vaccine manufacturing plant and released a couple of blistering observations on the cross-contamination, sanitary issues, and lack of staff training.
  • Today, Emergent responded to FDA’s observations with a comprehensive quality enhancement plan
  • Emergent said it has already started making improvements and is committed to making the necessary short and long-term enhancements to meet or exceed FDA’s standards. 
  • The company is continuing into an ongoing dialogue with the FDA and Johnson & Johnson to resume production. 
  • Price Action: EBS shares are trading 1.3% higher at $59.55 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareFDAGeneralBriefsCOVID-19 Vaccine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!